Remove Nursing Remove Patient Safety Remove Radiopharmaceuticals
article thumbnail

ARRS: How to manage the side effects of radiopharmaceuticals

AuntMinnie

Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer. It can be life-threatening, Major said, and the nursing team may need to know what to do.

article thumbnail

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

Imaging Technology

from October 1 to 4, 2023. Ulaner, MD, Ph.D., Hoag Family Cancer Institute, Irvine, Calif. and University of Southern California, Los Angeles, Calif.,